[ad_1] SINGAPORE, Dec. 5, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based…
Tag: Allogeneic
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology
[ad_1] The Company now has exclusive rights to a US and Chinese patent. SINGAPORE, Aug. 1, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical…